Brokerages predict that Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will post earnings of ($0.21) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Infinity Pharmaceuticals’ earnings. Infinity Pharmaceuticals posted earnings of ($0.39) per share during the same quarter last year, which suggests a positive year over year growth rate of 46.2%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.97). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.93) per share, with EPS estimates ranging from ($0.94) to ($0.91). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.12. During the same quarter last year, the business earned $1.05 earnings per share.

Several brokerages have commented on INFI. ValuEngine upgraded Infinity Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th. Zacks Investment Research downgraded Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th.

Infinity Pharmaceuticals (NASDAQ:INFI) opened at 1.05 on Tuesday. The company has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.95. The firm’s market cap is $53.22 million. Infinity Pharmaceuticals has a 1-year low of $0.84 and a 1-year high of $3.84.

Hedge funds and other institutional investors have recently modified their holdings of the business. Algert Global LLC bought a new position in Infinity Pharmaceuticals in the 1st quarter worth about $129,000. Dimensional Fund Advisors LP bought a new position in Infinity Pharmaceuticals in the 1st quarter worth about $1,588,000. Platinum Investment Management Ltd. boosted its stake in Infinity Pharmaceuticals by 62.6% in the 1st quarter. Platinum Investment Management Ltd. now owns 810,232 shares of the biotechnology company’s stock worth $2,617,000 after purchasing an additional 312,000 shares during the period. Nationwide Fund Advisors boosted its stake in Infinity Pharmaceuticals by 211.8% in the 1st quarter. Nationwide Fund Advisors now owns 96,918 shares of the biotechnology company’s stock worth $313,000 after purchasing an additional 65,838 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Infinity Pharmaceuticals by 27.7% in the 1st quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock worth $15,187,000 after purchasing an additional 1,021,128 shares during the period. Institutional investors and hedge funds own 67.47% of the company’s stock.

WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/05/infinity-pharmaceuticals-inc-infi-expected-to-post-earnings-of-0-21-per-share.html.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.